Back to today’s briefing

Story perspectives

FDA's Vinay Prasad to Depart Amid Controversial Tenure

3/11/2026

30 2 Full Breakdown

Summary

Story summary

Vinay Prasad will leave his post as director of the FDA's Center for Biologics Evaluation and Research (CBER) at the end of April 2026.
FDA Commissioner Marty Makary noted Prasad's efforts to implement significant reforms during his tenure.
His tenure included controversy, such as the rejection of an mRNA vaccine and allegations of staff abuse.
Prasad previously resigned from the FDA last summer but returned shortly after.

1 of 1

Story summary

Vinay Prasad will leave his post as director of the FDA's Center for Biologics Evaluation and Research (CBER) at the end of April 2026.
FDA Commissioner Marty Makary noted Prasad's efforts to implement significant reforms during his tenure.
His tenure included controversy, such as the rejection of an mRNA vaccine and allegations of staff abuse.
Prasad previously resigned from the FDA last summer but returned shortly after.